United States - English - NLM (National Library of Medicine)

morton grove pharmaceuticals, inc. - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 15 ml - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies.   since generlac solution (lactulose solution, usp) contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.  

United States - English - NLM (National Library of Medicine)

bajaj medical, llc - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia level by 25 to 50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose solution therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. controlled studies have shown that lactulose solution therapy reduces the blood ammonia level by 25 to 50%; this is generally paralleled by an improvement in the patients’ mental state and by an improvement in eeg patterns. the clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. an increase in patients’ protein tolerance is also frequently observed with lactulose solution therapy. in the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lactulose 66%{relative};   - syrup - 66% w/v - active: lactulose 66%{relative}  

New Zealand - English - Medsafe (Medicines Safety Authority)

technilab inc (nz) - lactulose 667 mg/ml - syrup - 667 mg/ml - active: lactulose 667 mg/ml excipient: purified water sodium hydroxide sunset yellow fcf

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis consumer health uk limited - lactulose - oral solution - 67 %w/v

Ireland - English - HPRA (Health Products Regulatory Authority)

resolution chemicals limited - lactulose - oral solution - 3.3 g/5ml

United States - English - NLM (National Library of Medicine)

cumberland pharmaceuticals inc. - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - lactulose 10 g in 10 g - kristalose® (lactulose) for oral solution is indicated for the treatment of constipation. in patients with a history of chronic constipation, lactulose therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since kristalose® (lactulose) for oral solution contains galactose (less than 0.3 g/10 g as a total sum with lactose), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

fresenius kabi austria gmbh - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the treatment of constipation. in patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.

United States - English - NLM (National Library of Medicine)

akorn - lactulose (unii: 9u7d5qh5ae) (lactulose - unii:9u7d5qh5ae) - for the treatment of constipation. in patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. since lactulose solution contains galactose (less than 1.6 g/15 ml), it is contraindicated in patients who require a low galactose diet.